Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.52 |
| ▸ | TRPM8 | Q7Z2W7 | 4/20 | 0.68 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | RAF1 | P04049 | 3/20 | 0.52 |
| ▸ | MAP2K1 | Q02750 | 3/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | APP | P05067 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14078338 | 0.99 | TRPM8 (0.69) | TRPM8MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL14078264 | 0.91 | TRPM8 (0.67) | TRPM8MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL5110070 | 0.91 | TRPM8 (0.81) | TRPM8MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL5184728 | 0.88 | TRPM8 (0.67) | TRPM8MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL14078347 | 0.88 | TRPM8 (0.69) | TRPM8MEN1KMT2AKDM4ECYP1A2 | |
| SCHEMBL14078259 | 0.88 | TRPM8 (0.65) | TRPM8MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL5110104 | 0.88 | TRPM8 (0.62) | TRPM8MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL5110881 | 0.86 | TRPM8 (0.79) | TRPM8MEN1KMT2AALDH1A1KDM4E | |
| Trifluoroacetic Acid SCHEMBL5114908 | 0.85 | TRPM8 (0.59) | TRPM8MEN1KMT2AALDH1A1KDM4E | |
| Hydrochloric Acid SCHEMBL5114925 | 0.84 | TRPM8 (0.62) | TRPM8MEN1KMT2AKDM4ECYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122030505-A | Use of TRPM8 inhibitors for improving animal productivity in cold conditions and method | 中国科学院动物研究所 | 2026-05-15 | — | — | CN | claimed |
| WO-2016187558-A2 | METHOD TO IMPROVE NEUROLOGIC OUTCOMES IN TEMPERATURE MANAGED PATIENTS | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2016-11-24 | — | — | WO | claimed |
| CN-122030505-A | Use of TRPM8 inhibitors for improving animal productivity in cold conditions and method | 中国科学院动物研究所 | 2026-05-15 | — | — | CN | disclosed |
| WO-2025088339-A1 | CONTACT LENS WITH TRPM8 AGONIST IS RELEASABLY ADHERED TO THE POLYMERIC LENS BODY | COOPERVISION INTERNATIONAL LIMITED (GB) | 2025-05-01 | — | — | WO | disclosed |
| US-12048685-B2 | Transient receptor potential cation channel subfamily m member 8 (TRPM8) antagonists and methods of use | ORA, INC. (US) | 2024-07-30 | — | — | US | disclosed |
| US-20230364189-A1 | Method to Improve Neurologic Outcomes in Temperature Managed Patients | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2023-11-16 | — | — | US | disclosed |
| US-20230172899-A1 | CANNABINOID COMPOSITIONS | THE QUEEN'S MEDICAL CENTER | 2023-06-08 | — | — | US | disclosed |
| US-11638745-B2 | Method to improve neurologic outcomes in temperature managed patients | University of Pittsburgh—Of the Commonwealth Cvctom of Hierher Education (US) | 2023-05-02 | — | — | US | disclosed |
| US-20230091336-A1 | CANNABINOID COMPOSITIONS | THE QUEEN'S MEDICAL CENTER | 2023-03-23 | — | — | US | disclosed |
| EP-4121020-A1 | CANNABINOID COMPOSITIONS | The Queen's Medical Center (US) | 2023-01-25 | — | — | EP | disclosed |
| EP-4110045-A1 | CANNABINOID COMPOSITIONS | The Queen's Medical Center (US) | 2023-01-04 | — | — | EP | disclosed |
| US-20180252700-A1 | SCREENING AGENTS IN DRY EYE DISEASE | ORA, INC. (US) | 2018-09-06 | — | — | US | disclosed |
| US-20180117120-A1 | Method to Improve Neurologic Outcomes in Temperature Managed Patients | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2018-05-03 | — | — | US | disclosed |
| WO-2018067895-A1 | SCREENING AGENTS IN DRY EYE DISEASE | ORA, INC. (US) | 2018-04-12 | — | — | WO | disclosed |
| US-20170258760-A1 | TRANSIENT RECEPTOR POTENTIAL CATION CHANNEL SUBFAMILY M MEMBER 8 (TRPM8) ANTAGONISTS AND METHODS OF USE | ORA, INC. (US) | 2017-09-14 | — | — | US | disclosed |
| WO-2017062570-A1 | TRANSIENT RECEPTOR POTENTIAL CATION CHANNEL SUBFAMILY M MEMBER 8 (TRPM8) ANTAGONISTS AND METHODS OF USE | ORA, INC. (US) | 2017-04-13 | — | — | WO | disclosed |
| WO-2016187558-A2 | METHOD TO IMPROVE NEUROLOGIC OUTCOMES IN TEMPERATURE MANAGED PATIENTS | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2016-11-24 | — | — | WO | disclosed |
| US-20080214654-A1 | Substituted Benzyloxy-Phenylmethylamide Derivatives | BAYER HEALTHCARE AG (DE) | 2008-09-04 | — | — | US | disclosed |
| EP-1802600-A1 | SUBSTITUTED 4-BENZYLOXY-PHENYLMETHYLAMIDE DERIVATIVES AS COLD MENTHOL RECEPTOR-1 (CMR-1) ANTAGONITS FOR THE TREATMENT OF UROLOGICAL DISORDERS | Bayer HealthCare AG (DE) | 2007-07-04 | — | — | EP | disclosed |
| WO-2006040136-A1 | SUBSTITUTED 4-BENZYLOXY-PHENYLMETHYLAMIDE DERIVATIVES AS COLD MENTHOL RECEPTOR-1 (CMR-1) ANTAGONISTS FOR THE TREATMENT OF UROLOGICAL DISORDER | BAYER HEALTHCARE AG (DE) | 2006-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180252700-A1 | SCREENING AGENTS IN DRY EYE DISEASE | ALDH1A2, FUCA2, FUCA1 | GAA 346/4885TRPM8 186/4885MEN1 4387/4885 |
| US-20170258760-A1 | TRANSIENT RECEPTOR POTENTIAL CATION CHANNEL SUBFAMILY M MEMBER 8 (TRPM8) ANTAGONISTS AND METHODS OF USE | TRPM8, TRPM2, TRPM7 | GAA 3594/4885TRPM8 1/4885MEN1 2269/4885 |
| US-20230172899-A1 | CANNABINOID COMPOSITIONS | CNR2, CNR1, GPR18 | GAA 3575/4885TRPM8 690/4885MEN1 997/4885 |
| US-20080214654-A1 | Substituted Benzyloxy-Phenylmethylamide Derivatives | OPRL1, ADRA1A, CNR1 | GAA 1314/4885TRPM8 124/4885MEN1 3278/4885 |
| US-20230091336-A1 | CANNABINOID COMPOSITIONS | CNR2, CNR1, GPR18 | GAA 3190/4885TRPM8 630/4885MEN1 1075/4885 |
| US-12048685-B2 | Transient receptor potential cation channel subfamily m member 8 (TRPM8) antagonists and methods of use | TRPM8, TRPM2, TRPM7 | GAA 3594/4885TRPM8 1/4885MEN1 2269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.